Key result
Oral anticoagulants were prescribed within 6 months to only 41.3% (7,604/18,404) of newly diagnosed atrial fibrillation patients at high risk for stroke.
Why the study?
Oral anticoagulants reduce stroke risk in atrial fibrillation, yet many patients do not receive timely therapy. This study used electronic health record data to identify high-risk, newly diagnosed AF patients who were not anticoagulated and the clinical factors associated with OAC prescription.
What patient demographic and clinical factors are associated with oral anticoagulant prescription within 6 months in patients with newly diagnosed atrial fibrillation at high risk for stroke?
Cohort (n=18,404)
Yes
What patient demographic and clinical factors are associated with oral anticoagulant prescription within 6 months in patients with newly diagnosed atrial fibrillation at high risk for stroke?
Less than half (41.3%) of newly diagnosed atrial fibrillation patients at high risk for stroke received timely oral anticoagulation within 6 months, with significant disparities based on sex, race, comorbidities, and concurrent medications.
Answers are grounded in this paper and cite their sources.
Low OAC prescription rates persist in high-risk AF; leaves open questions on barriers and equitable interventions.
Background Atrial fibrillation (AF) is the most common sustained arrhythmia in adults and increases stroke risk. Treatment with oral anticoagulants (OACs) may reduce this risk however many patients do not receive OAC therapy. This study aimed to use electronic health record data to identify newly diagnosed AF patients at high risk for stroke and not anticoagulated as well as factors associated with OAC prescription. Hypothesis Timely prescription of OACs among patients with newly diagnosed AF is poor. Methods We performed a retrospective study of patients with a new diagnosis of AF. We assessed stroke risk with the CHA2DS2‐VASc score. The primary outcome was prescription of an OAC within 6 months following diagnosis. We used logistic regression to see how the odds of being prescribed an OAC differs for 17 independent variables. Results We identified 18 404 patients with a new diagnosis of AF. Among patients at high risk for stroke, 41.3% received an OAC prescription within 6 months. Male sex, Caucasian compared to African American race, stroke, obesity, congestive heart failure, vascular disorder, current antiplatelet, beta blocker, or calcium channel blocker prescription, and increasing CHA2DS2‐VASc score were positively associated with receiving an OAC. Whereas anemia, renal dysfunction, liver dysfunction, antiarrhythmic drug use and increasing HAS‐BLED score were negatively associated. Conclusions Most newly diagnosed AF patients at high stroke risk do not receive an OAC prescription in the first 6 months following diagnosis. Our analysis suggests that patient sex, race, comorbidities, and additional prescriptions are associated with rates of OAC prescribing.
No takes yet. Share an insight, caveat, or question.
Manning et al. (2023) conducted a cohort in Newly diagnosed atrial fibrillation at high risk for stroke (n=18,404). Patient demographic and clinical factors (17 independent variables) was evaluated on Prescription of an oral anticoagulant (OAC) within 6 months following AF diagnosis. Oral anticoagulants were prescribed within 6 months to only 41.3% (7,604/18,404) of newly diagnosed atrial fibrillation patients at high risk for stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: